Lucintel Forecasts the Global Arthroscopy Devices Market to Reach $9.2 billion by 2030
According to a market report by Lucintel, the future of the global arthroscopy devices market looks promising with opportunities in the knee arthroscopy, hip arthroscopy, spine arthroscopy, shoulder and elbow arthroscopy markets. The global arthroscopy devices market is expected to reach an estimated $9.2 billion by 2030 from $6.0 billion in 2024, at a CAGR of 7.3% from 2024 to 2030
According to a market report by Lucintel, the future of the global arthroscopy devices market looks promising with opportunities in the knee arthroscopy, hip arthroscopy, spine arthroscopy, shoulder and elbow arthroscopy markets. The global arthroscopy devices market is expected to reach an estimated $9.2 billion by 2030 from $6.0 billion in 2024, at a CAGR of 7.3% from 2024 to 2030. The major drivers for this market are increasing incidences of sports injuries, rising geriatric population, and technological advancements in arthroscopic implants.
A more than 150-page report to understand trends, opportunity and forecast in arthroscopy devices market to 2030 by type (arthroscopes, arthroscopic implants, fluid management systems, radiofrequency systems, visualization systems, powered shavers, and others), application (knee arthroscopy, hip arthroscopy, spine arthroscopy, shoulder and elbow arthroscopy, and others), end use (ambulatory surgical centers, orthopedic clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the type category, arthroscopic implants will remain the largest segment over the forecast period due to the introduction of biodegradable implants and growing adoption of arthroscopic implants for internal tissue repair, bone grafting, joint fixation, and glenoid reconstruction.
Within the application category, knee arthroscopy will remain the largest segment due to growing number of people suffering from bone diseases like arthritis and rising senior population.
Download sample by clicking on arthroscopy devices market
In terms of regions, North America will remain the largest region over the forecast period due to the rising cases of bone-related disorders and presence of well-established healthcare infrastructure in the region.
Arthrex, Conmed Corporation, Johnson & Johnson, Karl Storz, Medtronic, Richard Wolf, Smith & Nephew, Stryker Corporation are the major suppliers in the arthroscopy devices market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. +1-972-636-5056
Explore Our Latest Publications
Infrastructure as a Service Market
Pulse Generator Market
Alternating Current (AC) Meters Sensors Market
Flexible Hybrid Electronics Market
Body Temperature Monitoring Market
Media Contact
Company Name: Lucintel
Contact Person: Roy Almaguer
Email: Send Email
Phone: 972.636.5056
Address: 8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
IonQ Announces Second Quarter Financial Results
IonQ (NYSE: IONQ), the leading commercial quantum computing and networking company, today announced financial results for the quarter ended June 30, 2025. "I am pleased to report that we beat the top end of guidance for Q2 revenue by 15%, and strengthened our balance sheet via the largest equity investment from a single institution in the quantum industry. We also made very tangible progress towards delivering our #AQ64 application performance benchmark, with strong indications that it will be achieved in the near term.' 'Via our closed acquisition of Lightsynq, along with our proposed acquisition of Oxford Ionics, we have created the most advanced and powerful quantum computing and networking roadmap in the world," said Niccolo de Masi, Chairman and CEO of IonQ. "The combination of IonQ hardware and software expertise and Oxford's implementation of ion-trap-on-a-chip provides the team, IP, technology, and momentum to achieve 800 logical qubits in 2027 and 80,000 logical qubits in 2030." 'The close of our acquisition of Capella in July expands our quantum networking vision to include a space-based QKD network," de Masi continued. 'Our networking products are production-grade and are used by many of the world's household-name financial services, telecom, and government agencies. IonQ quantum networking offers the ultimate in communication security, protecting even from the looming threat of quantum decryption." "We've also attracted world-class leaders who are choosing to build the future at IonQ. From the world of finance, Dr. Marco Pistoia has joined us after leading global applied research and quantum computing at JPMorgan Chase. From the highest levels of government, we welcomed Dr. Rick Muller, former Director of IARPA, the intelligence community's advanced research agency. To guide our corporate growth, veteran technology counsel Paul Dacier has taken the helm as Chief Legal Officer, and to sharpen our scientific core, our co-founder Dr. Chris Monroe has assumed the vital role of Chief Scientific Advisor.' 'As I have said before, I believe talent is the proverbial Warren Buffett weighing machine most relevant to any company's long-term prospects, and it is tremendously validating to have such towering figures in the quantum industry become our colleagues at IonQ." Financial Highlights IonQ recognized revenue of $20.7 million for the second quarter, which is 15% above the top end of the previously provided range. Cash, cash equivalents, and investments were $656.8 million as of June 30, 2025 and $1.6 billion pro-forma as of July 9, 2025. The balance increased due to the $1.0 billion equity financing. Net loss was $177.5 million and Adjusted EBITDA loss was $36.5 million for the second quarter.* *Adjusted EBITDA is a non-GAAP financial measure defined under 'Non-GAAP Financial Measures,' below, and is reconciled to net loss, its closest comparable GAAP measure, at the end of this release. Q2 and Recent Commercial Highlights IonQ announced the signing of a Memorandum of Understanding with KISTI to accelerate South Korea's role in the global quantum race, collaborating in four key areas: advanced infrastructure access, education, talent and knowledge exchange, and efforts to expand the quantum ecosystem. IonQ announced AI-focused collaboration with AIST in Japan through a Memorandum of Understanding, paving the way for joint R&D, workforce development initiatives, and access to IonQ Forte-class quantum computers to accelerate real-world quantum-AI applications. IonQ announced a partnership with Sweden's Einride to pioneer quantum-enhanced optimization for the global freight industry, collaborating to create quantum solutions for fleet routing, logistics optimization, and supply chain management. IonQ announced expansion across APAC through a strategic collaboration with Australian company Emergence Quantum, advancing IonQ's global expansion roadmap while strengthening Australia's quantum capabilities, with the Emergence Quantum team bringing decades of experience in trapped ion technology. IonQ backs landmark Texas Quantum Initiative, working with state leaders to position Texas as a U.S. quantum hub through policy support, investment incentives, and expanded opportunities in quantum computing, networking, and sensing technologies. IonQ announced that it secured a landmark $22M deal with utility leader EPB to create America's first commercial quantum hub, demonstrating significant commercial traction and strategic expansion into the critical energy infrastructure market. Q2 and Recent Technical Highlights IonQ announced a 20x speed-up of quantum-accelerated drug development applications with AstraZeneca, AWS, and NVIDIA, in the largest demonstration of its kind, combining leading hardware, platforms, and techniques, marking a significant step toward more efficient pharmaceutical production through hybrid quantum-classical workflows. IonQ announced that the Company and the University of Washington together achieved the first known quantum computer simulation of a process tied to the universe's matter–antimatter imbalance, modeling nuclear dynamics on unprecedented yoctosecond time-scales (10⁻²⁴ seconds) and potentially opening new frontiers in fundamental physics research. IonQ announced that it developed a hybrid quantum computing approach with Oak Ridge National Laboratory to drive power grid efficiencies and meet electricity demand at minimal cost. Q2 and Recent Corporate Highlights IonQ announced an agreement to acquire Oxford Ionics, creating the world's most advanced quantum computing roadmap when combined with IonQ. The combination promises 10,000 physical qubits with logical fidelities of 99.99999% by 2027 and 2 million physical qubits by 2030. IonQ announced the completion of its acquisition of Lightsynq, accelerating its quantum computing and quantum internet roadmaps and offering a clear path to millions of qubits through the integration of Lightsynq's advanced photonic interconnect technologies. IonQ announced the completion of its acquisition of Capella, facilitating its development of a space-based QKD network and the foundation of the quantum internet with the integration of Capella's satellite infrastructure. IonQ announced the pricing of a $1.0 billion equity offering, including shares and warrants, to strengthen its balance sheet to approximately $1.6 billion in pro-forma cash, for continued innovation and growth. IonQ announced the appointment of Marco Pistoia, renowned IBM inventor, quantum computing leader, and former Global Head of Applied Research and Quantum Computing at JPMorgan Chase, as Senior Vice President of Industry Relations. IonQ announced the expansion of its engineering leadership team with the hiring of Rick Muller, former Director of IARPA, as Vice President of Quantum Systems to advance its quantum hardware development. IonQ announced the appointment of Paul Dacier as Chief Legal Officer and Corporate Secretary to bolster its legal and governance framework amid rapid growth in quantum computing. IonQ announced the appointment of its founder Dr. Chris Monroe as Chief Scientific Advisor, where he will be working very closely with Dr. Mihir Bhaskar. IonQ announced that Dr. Grégoire Ribordy will remain in his role post-close to continue building on his 20 years of leadership in quantum networking. 2025 Financial Outlook For the full year 2025, IonQ expects revenue to be between $82 million and $100 million, with between $25 million and $29 million for the third quarter. 2025 Board Update IonQ announced that its Board of Directors has appointed CEO Niccolo de Masi to the additional position of Chairman of the Board, effective immediately. As a result, Peter Chapman has stepped down as Executive Chairman and as a member of the Board. Inder Singh, Lead Independent Director of IonQ, said, 'We are delighted to name Niccolo as Chairman of the Board. Since he became CEO in February 2025, Niccolo has excelled in leading the business forward. We are confident that he is the right person to guide our Board as we continue to oversee the execution of the Company's strategic priorities and the incredible momentum they are driving. We are grateful to Peter for his long-standing service to IonQ and wish him well.' de Masi commented, 'I am honored to receive this further vote of confidence in me by the Board as IonQ continues to extend its leadership in quantum computing and quantum networking. I also want to thank Peter for his seminal work in building the Company over the last six years and our collaboration over the last few months.' Second Quarter 2025 Conference Call IonQ will host a conference call today at 4:30 p.m. Eastern time to review the Company's financial results for the second quarter ended June 30, 2025 and to provide a business update. The call will be accessible by telephone at 844-826-3035 (domestic) or 412-317-5195 (international). The call will also be available live via webcast on the Company's website here, or directly here. A telephone replay of the conference call will be available approximately three hours after its conclusion at 844-512-2921 (domestic) or 412-317-6671 (international) with access code 10200658 and will be available until 11:59 p.m. Eastern time, August 20, 2025. An archive of the webcast will also be available here shortly after the call and will remain available for one year. Non-GAAP Financial Measures To supplement IonQ's condensed consolidated financial statements presented in accordance with GAAP, IonQ uses non-GAAP measures of certain components of financial performance. Adjusted EBITDA is a financial measure that is not required by or presented in accordance with GAAP. Management believes that this measure provides investors an additional meaningful method to evaluate certain aspects of the Company's results period over period. Adjusted EBITDA is defined as net loss attributable to IonQ, Inc. before net loss attributable to noncontrolling interests, interest income, interest expense, income tax (benefit) expense , depreciation and amortization expense, stock-based compensation, change in fair value of assumed warrant liabilities, acquisition transaction costs, and other non-recurring non-operating income and expenses. IonQ uses Adjusted EBITDA to measure the operating performance of its business, excluding specifically identified items that it does not believe directly reflect its core operations and may not be indicative of recurring operations. The presentation of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the financial results prepared in accordance with GAAP, and IonQ's non-GAAP measures may be different from non-GAAP measures used by other companies. IonQ shows a reconciliation of GAAP to non-GAAP financial measures at the end of this release. About IonQ IonQ, Inc. [NYSE: IONQ] is the leading commercial quantum computing and networking company , delivering high-performance systems aimed at solving the world's most complex problems. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results. The company is accelerating its technology roadmap and intends to deliver the world's most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ's advancements in quantum networking also positions the company as a leader in building the quantum internet. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'pending,' 'look forward,' 'accelerate,' 'anticipate,' 'expect,' 'suggests,' 'plan,' 'believe,' 'intend,' 'estimates,' 'targets,' 'projects,' 'should,' 'could,' 'would,' 'may,' 'will,' 'forecast,' 'offers' and other similar expressions are intended to identify forward-looking statements. These statements include those related to IonQ's position in the quantum computing and networking sector; the efficacy of new applications of quantum computing; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the success of partnerships and collaborations between IonQ and other parties, including development and commercialization of products and services with such parties; IonQ closing anticipated acquisitions; IonQ's ability to utilize the technology of acquired companies to accelerate the development and scale of IonQ's systems and offerings; advancement of quantum networking technology; the Company's technology driving commercial applications in the future; the Company's future financial and operating performance, including our preliminary outlook and guidance; the appearance of new applications of IonQ's products and services; the ability for third parties to implement IonQ's offerings to solve their problems and increase their quantum computing capabilities; expansion of IonQ's sales pipeline; IonQ's quantum computing capabilities and plans; future deliveries of and access to IonQ's quantum computers and services; future purchases of IonQ's offerings by customers using congressionally-appropriated funds from the U.S. government; IonQ's performance of existing contracts in the future, including anticipated timing of completion of research, development and manufacturing by IonQ; IonQ receiving additional revenues under planned subsequent phases of customer contracts; and the scalability and reliability of IonQ's quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates, including development of competing technologies; our ability to sell effectively to government entities and large enterprises; changes in laws and regulations affecting IonQ's and its suppliers' businesses; IonQ's ability to implement its business plans, forecasts and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ's ability to effectively integrate its acquisitions; its inability to effectively enter new markets; IonQ's ability to deliver services and products within currently anticipated timelines; its inability to attract and retain key personnel including personnel of acquired companies; the conditions for closing IonQ's anticipated acquisitions not being met; IonQ's customers deciding or declining to extend contracts into new phases; the inability of its suppliers to deliver components that meet expectations timely; changes in U.S. government spending or policy that may affect IonQ's customers; changes to U.S. government goals and metrics of success with regard to implementation of quantum computing and quantum networking; and risks associated with U.S. government sales, including availability of funding and provisions that allow the government to unilaterally terminate or modify contracts for convenience. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors'' section of IonQ's most recent periodic financial report (10-Q or 10-K) and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 20,694 $ 11,381 $ 28,260 $ 18,963 Costs and expenses: Cost of revenue (excluding depreciation and amortization) 8,327 5,623 12,642 9,037 Research and development 103,359 31,204 143,312 63,572 Sales and marketing 10,877 6,137 19,487 12,838 General and administrative 48,107 13,053 71,913 27,073 Depreciation and amortization 10,616 4,305 17,177 8,260 Total operating costs and expenses 181,286 60,322 264,531 120,780 Loss from operations (160,592 ) (48,941 ) (236,271 ) (101,817 ) Gain (loss) on change in fair value of warrant liabilities (39,577 ) 6,639 (1,083 ) 15,266 Interest income, net 7,138 4,801 12,032 9,600 Other income (expense), net 232 (45 ) 283 (179 ) Loss before income tax expense (192,799 ) (37,546 ) (225,039 ) (77,130 ) Income tax benefit (expense) 15,269 (15 ) 15,257 (23 ) Net loss $ (177,530 ) $ (37,561 ) $ (209,782 ) $ (77,153 ) Net loss attributable to noncontrolling interests (692 ) — (692 ) — Net loss attributable to IonQ, Inc. $ (176,838 ) $ (37,561 ) $ (209,090 ) $ (77,153 ) Net loss per share attributable to IonQ, Inc. common stockholders—basic and diluted $ (0.70 ) $ (0.18 ) $ (0.87 ) $ (0.37 ) Weighted average shares used in computing net loss per share attributable to IonQ, Inc. common stockholders—basic and diluted 250,967,455 211,637,479 239,924,680 209,898,459 IonQ, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 140,067 $ 54,393 Short-term investments 406,784 285,896 Accounts receivable, net 19,114 10,188 Prepaid expenses and other current assets 59,922 28,325 Total current assets 625,887 378,802 Long-term investments 109,902 23,545 Property and equipment, net 58,558 52,761 Operating lease right-of-use assets 11,254 9,470 Intangible assets, net 143,241 29,469 Goodwill 370,720 9,904 Other noncurrent assets 27,046 4,437 Total Assets $ 1,346,608 $ 508,388 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 8,938 $ 5,230 Accrued expenses and other current liabilities 49,190 16,424 Current portion of operating lease liabilities 5,528 3,366 Unearned revenue 16,726 10,678 Current portion of stock option early exercise liabilities 252 387 Total current liabilities 80,634 36,085 Operating lease liabilities, net of current portion 13,737 14,359 Unearned revenue, net of current portion 2,770 — Warrant liabilities 58,042 70,688 Other noncurrent liabilities 12,979 3,394 Total liabilities $ 168,162 $ 124,526 Stockholders' Equity: Common stock $ 27 $ 22 Additional paid-in capital 2,050,344 1,067,403 Accumulated deficit (892,810 ) (683,720 ) Accumulated other comprehensive income (loss) 4,072 157 Total IonQ, Inc. stockholders' equity $ 1,161,633 $ 383,862 Noncontrolling interests 16,813 — Total stockholders' equity $ 1,178,446 $ 383,862 Total Liabilities and Stockholders' Equity $ 1,346,608 $ 508,388 IonQ, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Six Months Ended June 30, 2025 2024 Cash flows from operating activities: Net loss $ (209,782 ) $ (77,153 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 17,177 8,260 Stock-based compensation 132,421 43,040 (Gain) loss on change in fair value of warrant liabilities 1,083 (15,266 ) Deferred income taxes (15,300 ) — Amortization of premiums and accretion of discounts on available-for-sale securities (3,540 ) (4,787 ) Other, net 1,502 2,156 Changes in operating assets and liabilities: Accounts receivable (3,595 ) 3,558 Prepaid expenses and other current assets (25,142 ) (8,341 ) Accounts payable 1,094 (165 ) Accrued expenses and other current liabilities 20,741 (2,116 ) Unearned revenue (4 ) 1,262 Other assets and liabilities (2,254 ) 2,508 Net cash provided by (used in) operating activities $ (85,599 ) $ (47,044 ) Cash flows from investing activities: Purchases of property and equipment (3,501 ) (10,629 ) Capitalized software development costs (1,886 ) (2,129 ) Intangible asset acquisition costs (307 ) (892 ) Purchases of available-for-sale securities (435,130 ) (146,098 ) Maturities of available-for-sale securities 211,180 211,572 Businesses acquired, net of cash paid 28,667 — Net cash provided by (used in) investing activities $ (200,977 ) $ 51,824 Cash flows from financing activities: Proceeds from at-the-market offering, net of issuance costs 358,254 — Proceeds from stock options exercised 7,564 1,185 Proceeds from public warrants exercised 5,592 — Tax withholding receipts (payments) related to vested and released RSUs, net 1,447 141 Net cash provided by (used in) financing activities $ 372,857 $ 1,326 Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash 391 4 Net change in cash, cash equivalents and restricted cash 86,672 6,110 Cash, cash equivalents and restricted cash at the beginning of the period 56,840 38,081 IonQ, Inc. (unaudited) (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss attributable to IonQ, Inc. $ (176,838 ) $ (37,561 ) $ (209,090 ) $ (77,153 ) Net loss attributable to noncontrolling interests (692 ) — (692 ) — Interest income, net (7,138 ) (4,801 ) (12,032 ) (9,600 ) Interest expense — — — — Income tax (benefit) expense (15,269 ) 15 (15,257 ) 23 Depreciation and amortization 10,616 4,305 17,177 8,260 Stock-based compensation 99,168 20,979 132,421 43,040 (Gain) loss on change in fair value of warrant liabilities 39,577 (6,639 ) 1,083 (15,266 ) Acquisition transaction costs 14,060 — 15,841 —
Globe and Mail
2 hours ago
- Globe and Mail
Speeding up generic drug approval timelines a priority, health minister says
The federal government is committed to speeding up drug approval timelines as part of Prime Minister Mark Carney's drive to improve efficiency and cut red tape, Health Minister Marjorie Michel said in an interview. The Globe and Mail reported this week on new data that showed Health Canada is increasingly failing to review generic drug applications within its 180-day target, meaning cheaper pharmaceuticals are taking longer to get to market. That is on top of Canada's historically slow timelines for all drugs, which rank among the longest in developed countries. Ms. Michel said that, while safety can't be compromised, it is clear there are ways to make the approval process more efficient and she has asked her department to report to her regularly on timelines. 'It's a priority for me,' she said in an interview Tuesday. Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers The Liberals promised in the spring election to 'significantly reduce' wait times for pharmaceuticals, which it acknowledged were longer than in other Group of Seven countries. 'By cutting red tape without compromising on safety we will cut this timeline while maintaining all relevant safety standards, supporting our research community and delivering life-saving medicines more quickly,' the Liberal campaign platform said. Health Canada has said one reason for delays in generics applications is incomplete or inadequate documentation from pharmaceutical companies. Data reported by The Globe this week showed that, in the 2024-25 fiscal year, 70 per cent of applications received a ruling in the final week before the 180-day target. In about three-quarters of those cases, the applications were rejected and Health Canada requested further information. But 90 per cent of applications were ultimately approved, leading the Canadian Generic Pharmaceutical Association, which represents generic drug makers, to argue that the early rejections are more a sign of files being picked up too late and not because of underlying deficiencies with the drugs. Ms. Michel said one relatively straightforward solution is earlier screening of applications. 'Where I can push is, yeah, we cannot take eight months to let them know' when there are paperwork issues, she said. 'If work has to be done, then the person needs to know as soon as possible.' Sandoz to reportedly offer generic weight-loss drugs in Canada at up to 70% discount Another area of improvement the minister identified is better collaboration with regulators in other countries. Most large pharmaceutical companies operate globally and have to work with regulators in other countries. They often question why Canadian regulators take longer than European peers. 'I would say also that what I'm encouraging my department to do a lot is to lean on approvals done by like-minded partners,' Ms. Michel said. 'Because if a drug is approved somewhere, we trust that [they] have the same regulations than we have or quite the same, well, maybe it can speed up the process.' Not all parts of the drug approval process are under federal control. The final stage of the pathway is when drug makers go to the pan-Canadian Pharmaceutical Alliance to negotiate pricing deals with all federal, provincial and territorial public insurance plans. In those discussions, Ottawa is one of 14 seats at the table. Ms. Michel said she is working with provincial counterparts on this issue, although it is one of many urgent health problems the system is facing. 'You know, they are overwhelmed, maybe with primary care,' she said of the provinces, adding that it is her role to bring everyone to the table and 'see how we can, you know, speed the process.' She said one of Canada's major strengths is its research sector. She said that will continue to be a focus and pointed to an announcement of $1.3-billion in research funding she and Industry Minister Mélanie Joly made in July. 'We have to deliver on this,' she said.
Globe and Mail
3 hours ago
- Globe and Mail
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.95 in the second quarter of 2025, up 13.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.3%. GAAP EPS for the quarter was $2.58, reflecting an uptick of 3.2% year over year. DaVita's Revenues in Detail Revenues of $3.38 billion in the second quarter increased 6.1% year over year. The figure topped the Zacks Consensus Estimate by 1.3%. Revenue per treatment in the second quarter of 2025 was $404.6 million, up 3.7% year over year and 1.1% sequentially. Per management, this was primarily driven by normal seasonal improvements, including patients meeting their co-insurance and deductibles. This was partially offset by decreased volume of phosphate binders. Shares of this company plunged nearly 10.1% till last trading. DVA's Segment Details DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues. The dialysis patient service revenues were $3.21 billion, up 4.8% year over year. Other revenues were $172.7 million, up 37.4% from the year-ago quarter's figure. Per management, the total U.S. dialysis treatments for the second quarter were 7,186,217 or 92,131 per day, on average. This represents a per-day increase of 0.4% on a sequential basis. Normalized non-acquired treatment declined 0.8% year over year in the second quarter of 2025. As of June 30, 2025, DaVita provided dialysis services to around 283,100 patients at 3,175 outpatient dialysis centers, of which 2,662 were U.S. centers while 513 were located across 13 other countries. During the second quarter of 2025, the company acquired one, opened three and closed two dialysis centers in the United States. It also opened six and closed five dialysis centers outside the United States in the same period. As of June 30, 2025, DaVita had approximately 64,400 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.3 billion in annualized medical spend. The company also had an additional 9,300 patients in other integrated care arrangements. DaVita's Margin Details In the quarter under review, DaVita's gross profit increased 7% year over year to $1.12 billion. The gross margin expanded 31 basis points (bps) to 33.1%. General & administrative expenses climbed 12.2% year over year to $412.8 million. Adjusted operating profit totaled $705.2 million, reflecting a 4.2% increase from the prior-year quarter's level. Adjusted operating margin in the second quarter contracted 36 bps to 20.9%. DVA's Financial Position DaVita exited second-quarter 2025 with cash and cash equivalents and short-term investments of $739.4 million compared with $511.9 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2025 was $10.26 billion compared with $9.74 billion at the first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter 2025 was $504.2 million compared with $664 million a year ago. During the three months ended June 30, 2025, DVA repurchased 3.1 million shares for $446 million. DaVita's Guidance DaVita has reiterated its adjusted EPS outlook for 2025. Adjusted EPS for the full year is continued to be projected in the range of $10.20-$11.30. The Zacks Consensus Estimate currently stands at $10.76. Our Take on DVA DaVita ended the second quarter of 2025 with better-than-expected results. The uptick in the company's top and bottom lines and revenue per treatment was encouraging. The per-day increase in total U.S. dialysis treatments for the second quarter on a sequential basis and solid revenues from both sources were encouraging. The opening and acquiring of dialysis centers within the United States and acquiring centers overseas were promising. The gross margin expansion bodes well for the stock. However, the year-over-year decline in normalized non-acquired treatment was disappointing. The contraction of the adjusted operating margin does not bode well for the stock. DaVita's Zacks Rank and Key Picks DVA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
